title: Healing patterns of critical size bony defects in rats after grafting with bone substitutes soaked in recombinant human bone morphogenetic protein-2: histological and histometric evaluation.
abstract: The aim of the study was to evaluate the effect of different bone substitutes soaked in recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of critical size defects in calvarial bone. Defects were created in 24 Sprague Dawley rats. The rhBMP-2 was diluted to obtain a final concentration of 0.2mg/ml. Rats were divided into four groups and treated as follows: in the first group the defect was filled with anorganic bovine bone mineral (ABBM) and rhBMP-2, the second group was treated with freeze-dried bone allograft (FDBA) and rhBMP-2, and the third group was treated with autogenous bone (AUTO). In the control group the defects were left untreated. Animals were killed after 8weeks and calcified histological sections prepared. Histometric measurements showed that mean (SD) bone formation was 4.00 (1.69)mm(2) in the ABBM group, 2.56 (1.06)mm(2) in the FDBA group, and 2.30 (0.34)mm(2) in the AUTO group. The difference between the ABBM group and the other 3 groups was significant (p<0.0001) with a mean bone formation of 0.82 (0.25)mm(2) in the control group. There was no significant difference between the FDBA and the AUTO groups (p=0.96). Within the limits of this study we concluded that the addition of rhBMP-2 to bone substitutes was efficacious in regenerating bone in critical size bone defects in calveria in rats.
authors.affiliation: Department of Periodontology, School of Dentistry, Saint-Joseph University, P.O. Box 11-5076, Riad el Solh, Beirut 1107 2050, Lebanon. nadim.mokbel@usj.edu.lb
authors.forename: N
authors.initials: N
authors.lastname: Mokbel
authors.forename: N
authors.initials: N
authors.lastname: Naaman
authors.forename: J
authors.initials: J
authors.lastname: Nohra
authors.forename: N
authors.initials: N
authors.lastname: Badawi
mesh_terms: D064591:Allografts / Q000637:transplantation; D000818:Animals; D064592:Autografts / Q000637:transplantation; D001847:Bone Diseases / Q000601:surgery*; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000502:physiology; D018786:Bone Substitutes / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods; D002417:Cattle; D003393:Cranial Sutures / Q000473:pathology / Q000601:surgery; D005624:Frontal Bone / Q000473:pathology / Q000601:surgery; D006801:Humans; D008903:Minerals / Q000627:therapeutic use*; D010012:Osteogenesis / Q000502:physiology; D010294:Parietal Bone / Q000473:pathology / Q000601:surgery*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014945:Wound Healing / Q000502:physiology
chemical_list: C077540:Bio-Oss; D055396:Bone Morphogenetic Protein 2; D018786:Bone Substitutes; D008903:Minerals; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2